company background image
ELYM logo

Eliem Therapeutics NasdaqGM:ELYM Stock Report

Last Price

US$2.76

Market Cap

US$76.5m

7D

-1.1%

1Y

-10.1%

Updated

27 Mar, 2024

Data

Company Financials

Eliem Therapeutics, Inc.

NasdaqGM:ELYM Stock Report

Market Cap: US$76.5m

ELYM Stock Overview

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems.

ELYM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Eliem Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eliem Therapeutics
Historical stock prices
Current Share PriceUS$2.76
52 Week HighUS$3.72
52 Week LowUS$2.34
Beta0.50
1 Month Change4.55%
3 Month Change1.10%
1 Year Change-10.10%
3 Year Changen/a
5 Year Changen/a
Change since IPO-82.64%

Recent News & Updates

Recent updates

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01
Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24
We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Mar 08
We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Nov 18
We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Aug 15

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Aug 02

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

Jul 11

Shareholder Returns

ELYMUS BiotechsUS Market
7D-1.1%0.9%0.4%
1Y-10.1%10.3%28.8%

Return vs Industry: ELYM underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: ELYM underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is ELYM's price volatile compared to industry and market?
ELYM volatility
ELYM Average Weekly Movement7.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ELYM has not had significant price volatility in the past 3 months.

Volatility Over Time: ELYM's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201837n/ahttps://eliemtx.com

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

Eliem Therapeutics, Inc. Fundamentals Summary

How do Eliem Therapeutics's earnings and revenue compare to its market cap?
ELYM fundamental statistics
Market capUS$76.49m
Earnings (TTM)-US$39.24m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ELYM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$39.24m
Earnings-US$39.24m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.42
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ELYM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.